Cold plasma with zirconia nanoparticles for lung cancer via TGF-\b{eta} signaling pathway

Despite advancements in lung cancer therapy, the prognosis for advanced or metastatic patients remains poor, yet many patients eventually develop resistance to standard treatments leading to disease progression and poor survival. Here, we described a combination of CAP and nanoparticles (ZrO2 NPs (zirconium oxide nanoparticle) and 3Y-TZP NPs (3% mol Yttria Tetragonal Zirconia Polycrystal Nanoparticle)) for lung cancer therapy. We found that ZrO2 NPs caused obvious damage to the inside of the lung cancer cells. CAP and ZrO2 NPs mainly affected the mitochondria function, leading to a decrease in mitochondrial membrane potential and ATP levels, and causing endoplasmic reticulum stress and cell nucleus internal DNA damage, etc. CAP combined with ZrO2 NPs (CAP@ZrO2) induced lung cancer cell apoptosis by activating the TGF-\b{eta} pathway. CAP@ZrO2 offers a new therapy for the clinical treatment of lung cancer.